Supplementary table

Supplementary table 1. Primers used for transcript quantification by RT-PCR

	<u> </u>	
Gene ^a	Primer sequences (5'-3') b	
Mus ANP F	TCGGAGCCTACGAAGATCCA	
Mus ANP R	GTGGCAATGTGACCAAGCTG	
Mus BNP F	GTTTGGGCTGTAACGCACTG	
Mus BNP R	TTGTGGCAAGTTTGTGCTCC	
Mus β-MHC F	CTTACTTGCTACCCTCAGGTGG	
Mus β-MHC R	ATGGCTGAGCCTTGGATTCTC	
Mus TGF-β F	TGGCCAGATCCTGTCCAAAC	
Mus TGF-β R	CATAGATGGCGTTGTTGCGG	
Mus Collagen I F	TTCTCCTGGCAAAGACGGAC	
Mus Collagen I R	CTCAAGGTCACGGTCACGAA	
Mus Collagen III F	CAAGGCTGCAAGATGGATGC	
Mus Collagen III R	TGCACCAGAATCTGTCCACC	
Mus sGC-β F	ACAGGTGTCTCATGTCTCCA	
Mus sGC-β R	GTGCTCCTTGCTTGACACAC	
Mus SGLT2 F	GCTGGATTTGAGTGGAATGC	
Mus SGLT2 R	CGGTCAGATACACTGGCACA	
Mus Fis1 F	CAAAGAGGAACAGCGGGACT	
Mus Fis1 R	ACAGCCCTCGCACATACTTT	
Mus Drp1 F	ATGCCAGCAAGTCCACAGAA	
Mus Drp1 R	TGTTCTCGGGCAGACAGTTT	
Mus Mfn1 F	GCAGACAGCACATGGAGAGA	
Mus Mfn1 R	GATCCGATTCCGAGCTTCCG	
Mus Mfn2 F	TGCACCGCCATATAGAGGAAG	
Mus Mfn2 R	TCTGCAGTGAACTGGCAATG	
Mus β-actin F	CCTCTATGCCAACACAGTGC	
Mus β-actin R	ACATCTGCTGGAAGGTGGAC	

^a Mus, mouse; ^b F, forward primer; R, reverse primer.

Supplementary table 2. General and echocardiographic features of db/db mice with or without insulin treatment.

	db/db	db/db+insulin
Body weight (g)	49.67±3.89	51±3.69
Blood glucose (mmol/L)	27.03±2.84	16.40±2.90***

HW/TL (mg/mm)	10.69±1.40	10.34±0.81
EF (%)	54.73±5.28	51.02±4.74
FS (%)	29.58±3.65	27.68±2.93
IVRT (ms)	23.46±2.50	24.92±3.17
DT (ms)	33.54±3.69	35.66±2.86
E/A	1.26±0.22	1.19±0.15

Mice in the db/db+insulin group (n=6) were injected the adjusted dose of insulin glargine (Sanofi-Aventis Pharmaceuticals, NJ) subcutaneously. Mice in the db/db (n=6) group were injected the same volume of normal saline as the db/db+insulin group. Data are presented as mean±SD, n=8 per group. ***P<0.001 represents significant differences between db/db and db/db+insulin mice. Abbreviations: DT, deceleration time; E/A, velocity of early mitral flow to velocity of late mitral flow ratio; EF, ejection fraction; FS, fraction shortening; HW/TL, heart weight to tibia length ratio; IVRT, isovolumetric relaxation time.

Supplementary figures

Supplementary figure 1




Figure S1. Relative mRNA expression of SGLT2 in heart and kidney. Data are presented as mean \pm SD, n=6 per group. ***P<0.001 represents significant differences between heart and kidney.

Supplementary figure 2




Figure S2. Changes in proteins related to mitochondrial dynamics. (A-D) mRNA expression of Fis1, Drp1, Mfn1 and Mfn2 was measured by quantitative RT-PCR, n=6 per group. ***P<0.001 represents significant differences between db/m and db/db mice; ##P<0.01 and #P<0.05 represent significant differences between db/db and db/db+Empa. Abbreviations: Drp1, Dynamin related protein 1; Fis1, fission; Mfn1, mitofusin 1; Mfn2, mitofusin 2.

Supplementary figure 3




Figure S3. Downregulation of sGC-β undermined the effect of empagliflozin on diabetic heart. (**A**) mRNA expression of sGC-β was measured by quantitative RT-PCR after transfection in different groups, n=6 per group. (**B-C**) Representative levels of cGMP in serum and myocardium were evaluated by Elisa, n=4 per group. (**D**) Protein expression of p-eNOS, t-eNOS, sGC-β, PKG1α, p-VASP and t-VASP in myocardium were determined by western blot. (**E-F**) Quantitative analysis of p-eNOS/t-eNOS, sGC-β, PKG1α and p-VASP/t-VASP for western blot, n=4 per group. Data are presented as mean±SD. ***P<0.001, **P<0.01 and *P<0.05 represent significant differences between db/db and db/db+Empa mice; ##P<0.001,

##P<0.01 and #P<0.05 represent significant differences between db/db+Empa+si-NC and db/db+Empa+si-sGC- β .